About AIxMed
AIxMed, Inc. is a digital pathology company that develops AI-driven computational cytology platforms to transform cancer diagnosis and monitoring. Founded in 2018, the company operates at the intersection of computer science and healthcare, combining advanced artificial intelligence with traditional cytology analysis to improve clinical outcomes and reduce healthcare burdens. The company's flagship product, AIxURO, is an AI-powered software platform for urinary cytology that revolutionizes urine cytology evaluation through advanced artificial intelligence, morphology analysis, and quantitative statistics. AIxURO analyzes and categorizes suspicious and atypical cells using non-invasive urine samples, providing whole-slide intelligence where every cell is analyzed, ranked, and presented in a gallery view from most to least suspicious. The platform integrates into existing laboratory workflows and is compatible with multiple slide imaging systems and Papanicolaou stained slide preparation methods including Cytospin, SurePath, ThinPrep, and Direct Manual Review. AIxMed is expanding its platform across multiple cancer types, with AIxTHY for thyroid cytology, AIxPAP for cervical cytology, and AIxPUL for pulmonary cytology currently in development. The company's solutions are designed for research use only and support pathology laboratories, health systems, and research institutions in improving workflow efficiency, standardizing data analysis, and enhancing the quality of cytology review. AIxMed's technology has been trained on thousands of slides and cells, providing comprehensive cell-level morphological data, quantitative metrics including N/C ratios and nucleus area measurements, and detailed slide-level statistics to support structured cytology research workflows.
Mission & Story
Mission
Our vision is more than an idea. It's a tangible roadmap to transforming cancer diagnosis and monitoring through our smart computational cytology platform.
Founding Story
In 2018, AIxMed's founders blended their divergent, respective backgrounds to break through the traditional cytology status quo. Samuel Chen brings AI technology ingenuity and leadership experience from ASUS and Compal. Dr. Tien-Jen Liu offers medical expertise as a trained physician and serial medtech entrepreneur. Their combined diversity of thought will make a meaningful impact in healthcare, with intuitive commercialized tools to simplify laboratory workflows and strengthen the quality of cytology analysis.
Clinical Focus
Medical conditions and clinical areas addressed by AIxMed.
Who It Serves
Milestones & Awards
Recent Milestones
AIxURO launched and in use by pathology partners. Three additional platforms (AIxTHY, AIxPAP, AIxPUL) in development and marked as 'coming soon'.
Awards & Recognition
Team includes award-winning cytopathologists and contributing authors of The Paris System (TPS) for Reporting Urinary Cytology
Key Partnerships
Company Details
- Founded
- 2018
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingOfficial Sources
Similar Companies in this Market
View all 45 →
Aiforia
Aiforia provides AI-powered digital pathology solutions for clinical diagnostics and research. The company offers cloud-based deep learning tools and CE-IVD marked clinical suites for analyzing pathology images across multiple cancer types, serving pathologists, researchers, and diagnostic laboratories worldwide.
Aignostics
Aignostics develops AI-powered pathology solutions for precision medicine, specializing in tumor microenvironment analysis from H&E-stained whole slide images. The company serves life sciences companies and academic researchers with foundation models and custom analytics services.
Aiosyn
Aiosyn develops AI-powered computational pathology software that integrates into standard digital pathology workflows. The company specializes in deep learning solutions for cancer and chronic kidney disease diagnostics, serving clinical laboratories, biopharma, and CROs.
Akoya Biosciences
Akoya Biosciences, now part of Quanterix, provides spatial biology solutions for high-plex tissue analysis. The company develops instruments, assays, and software for spatial proteomics research, enabling researchers to map biomarkers at single-cell resolution in tissue samples.
Caris Life Sciences
Caris Life Sciences is a leading precision medicine company that provides comprehensive molecular profiling for cancer patients. The company combines genomic, transcriptomic, and proteomic data with AI to deliver personalized treatment insights for oncologists and patients.
CellaVision
201-500 employees
CellaVision is a world-leading provider of digital hematology microscopy solutions covering analyzers, instruments, reagents, and software. The company automates workflows in hematology laboratories of all sizes for human and animal blood and body fluid sample analysis.
Clever Culture Systems
Clever Culture Systems develops AI-powered automated microbiology culture plate reading technology for pharmaceutical and clinical laboratories. Their flagship product, APAS Independence, automates the imaging, interpretation, and reporting of microbial growth on culture plates.
Cognoa
Cognoa is an early childhood development and pediatric behavioral health company developing digital diagnostics and therapeutics. Their flagship product, Canvas Dx, is the first FDA-authorized AI-powered diagnostic solution for autism in children ages 1.5-6 years, enabling diagnosis within days instead of months or years.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.